ARV-102: First-in-Human Data Shows Blood-Brain Barrier Penetration
Arvinas presented positive Phase 1 clinical trial data for ARV-102, a PROTAC degrader targeting LRRK2, a protein implicated in...
Anavex Life Sciences Announces Positive 4-Year Blarcamesine Results
Anavex Life Sciences announced positive data from its ATTENTION-AD trial, a long-term extension of a Phase 2b/3 study evaluating...
GlucoTrack & OneTwo Analytics Partner for CGM Clinical Study
Glucotrack, Inc. (Nasdaq: GCTK) is partnering with OneTwo Analytics AB to analyze clinical study data from its Continuous Blood...
Neurona Therapeutics Raises $102M for Epilepsy Cell Therapy Trial
Neurona Therapeutics secured $102 million in an oversubscribed financing round to advance its allogeneic cell therapy candidate, NRTX-1001, for...
Cingulate Completes Pre-NDA Meeting with FDA for CTX-1301
Cingulate Inc. held a Pre-NDA meeting with the FDA to discuss its new drug application for CTx-1301, a treatment...
Pacira Initiates Phase 2 Osteoarthritis Knee Study
Pacira BioSciences has initiated a Phase 2 clinical trial, ASCEND, for PCRX-201, a locally administered gene therapy designed to...
Neurona Therapeutics Raises $102M for Epilepsy Cell Therapy Trial
Neurona Therapeutics secured $102 million in an oversubscribed financing round, fueled by positive clinical data from its ongoing Phase...
Coaptium Connect System’s Clinical Results for Nerve Repair
TISSIUM’s COAPTIUM® CONNECT System, a novel sutureless solution for peripheral nerve repair, has shown promising results in a clinical...
Alpha Tau FDA Clearance for Recurrent Glioblastoma Trial
Alpha Tau Medical (NASDAQ: DRTS, DRTSW) received FDA clearance for an Investigational Device Exemption (IDE) to begin a pilot...
FibroBiologics Announces Breakthrough Brain Tissue Repair Results
FibroBiologics, a clinical-stage biotech company, announced positive results from a preclinical study investigating the use of intravenous fibroblasts to...